STOCK TITAN

EXELIXIS (EXEL) SEC Filings, May 22-29, 2026

EXEL NASDAQ

Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.

Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.

Rhea-AI Summary

Freire Maria C reported acquisition or exercise transactions in this Form 4 filing.

EXELIXIS, INC. director Maria C. Freire received a grant of 8,367 restricted stock units (RSUs) on May 27, 2026 under the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU equals one share of common stock and will vest 100% on May 27, 2027, subject to her continuous service. After this award, she directly holds 109,186 shares of common stock, including the shares underlying these RSUs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.40%
Tags
insider
-
Rhea-AI Summary

Beckerle Mary C reported acquisition or exercise transactions in this Form 4 filing.

EXELIXIS, INC. director Mary C. Beckerle received a grant of 8,367 restricted stock units (RSUs), each equal to one share of common stock. The award was granted under the 2017 Equity Incentive Plan and will vest in full on May 27, 2027, subject to continuous service. Following this grant, she holds 25,891 shares and RSUs, including 16,079 shares issuable upon future RSU vesting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.40%
Tags
insider
-
Rhea-AI Summary

Oliver Bob reported acquisition or exercise transactions in this Form 4 filing.

EXELIXIS, INC. director Oliver Bob received a grant of 8,367 shares of Common Stock in the form of restricted stock units as compensation. The RSUs were granted at no cash cost and will vest in full on May 27, 2027, if he remains in continuous service. After this award, he directly holds 29,487 shares, including 17,455 shares that will be issued upon vesting of existing RSUs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.40%
Tags
insider
Rhea-AI Summary

WYSZOMIERSKI JACK L reported acquisition or exercise transactions in this Form 4 filing.

Exelixis, Inc. director Jack L. Wyszomierski received a grant of 8,367 restricted stock units, each equal to one share of common stock, under the 2017 Equity Incentive Plan. The RSUs vest in full on May 27, 2027, subject to continuous service, bringing his reported holdings to 288,309 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.40%
Tags
insider
-
Rhea-AI Summary

POSTE GEORGE reported acquisition or exercise transactions in this Form 4 filing.

EXELIXIS, INC. director George Poste received a grant of 8,367 restricted stock units, each equal to one share of common stock and granted at no cost, under the company’s 2017 Equity Incentive Plan. The RSUs vest in full on May 27, 2027, subject to his continuous service. After this award, he directly beneficially owns 127,199 shares of common stock, including the unvested RSUs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.40%
Tags
insider
-
Rhea-AI Summary

EXELIXIS, INC. director David Edward Johnson reported receiving an option grant covering 19,133 shares of common stock. The option has an exercise price of $50.03 per share, is exercisable immediately subject to repurchase provisions, and expires on May 26, 2033. It will vest in full on the first anniversary of the grant date, conditioned on Mr. Johnson’s continuous service. After this award, he holds options for 19,133 shares. Footnotes state the securities are deemed held for the benefit of Caligan Partners Master Fund LP and certain managed accounts of Caligan Partners LP, and may be transferred to those entities after vesting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.40%
Tags
insider
Rhea-AI Summary

Exelixis, Inc. reported the results of its 2026 annual stockholder meeting. Stockholders approved an amended and restated 2017 Equity Incentive Plan, which became effective immediately upon approval. All 11 director nominees were elected to serve until the next annual meeting in 2027.

Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending January 1, 2027. They also approved, on an advisory basis, the compensation of Exelixis’ named executive officers, confirming support for the company’s current governance and compensation framework.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.40%
Tags
current report
-
Rhea-AI Summary

EXELIXIS, INC. executive Dana Aftab, EVP of Research and Development, reported an open-market sale of Common Stock. On May 26, 2026, Aftab sold 43,451 shares of Exelixis common stock at $50.35 per share.

After this transaction, Aftab directly holds 594,741 shares of common stock. In addition, a separate entry shows 5,835 shares held indirectly through the Exelixis 401(k) Plan. Footnotes also note 405,966 shares that may be issued upon vesting of restricted stock units and performance-based restricted stock units, each representing the right to receive one share of common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
insider
-
Rhea-AI Summary

EXELIXIS, INC. (EXEL) officer Dana T. Aftab gave notice of a proposed sale of 43,451 common shares, with an aggregate market value of $2,187,757.85 and an approximate sale date of May 26, 2026. The notice lists 251,355,083 common shares outstanding and names Morgan Stanley Smith Barney LLC as broker. Listed acquisition sources include restricted-stock vesting, performance stock units and employee stock purchase plan purchases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.10%
Tags
other
Rhea-AI Summary

Exelixis, Inc. executive Patrick J. Haley reported an open‑market sale of 32,110 shares of Common Stock. The shares were sold at a weighted average price of $49.81 per share, with individual trades ranging from $49.80 to $49.89.

After this transaction, Haley directly holds 357,638 shares of Exelixis common stock. Footnote disclosure states that this figure includes 356,992 shares that will be issued upon vesting of restricted stock units and a performance-based restricted stock unit award, each convertible into one share of common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
insider

FAQ

How many EXELIXIS (EXEL) SEC filings are available on StockTitan?

StockTitan tracks 102 SEC filings for EXELIXIS (EXEL), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for EXELIXIS (EXEL)?

The most recent SEC filing for EXELIXIS (EXEL) was filed on November 9, 2026.